Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Role of TGF-β signaling in inherited and acquired myopathies.

Burks TN, Cohn RD.

Skelet Muscle. 2011 May 4;1(1):19. doi: 10.1186/2044-5040-1-19.

2.

Transforming growth factor-beta and myostatin signaling in skeletal muscle.

Kollias HD, McDermott JC.

J Appl Physiol (1985). 2008 Mar;104(3):579-87. Epub 2007 Nov 21. Review.

3.

The TGF-β Signalling Network in Muscle Development, Adaptation and Disease.

Chen JL, Colgan TD, Walton KL, Gregorevic P, Harrison CA.

Adv Exp Med Biol. 2016;900:97-131. doi: 10.1007/978-3-319-27511-6_5. Review.

PMID:
27003398
4.

An inhibitor of transforming growth factor beta type I receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy.

Ohsawa Y, Okada T, Nishimatsu S, Ishizaki M, Suga T, Fujino M, Murakami T, Uchino M, Tsuchida K, Noji S, Hinohara A, Shimizu T, Shimizu K, Sunada Y.

Lab Invest. 2012 Aug;92(8):1100-14. doi: 10.1038/labinvest.2012.78. Epub 2012 May 14.

5.

Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia.

Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL, Walston JD, Ward CW, Cohn RD.

Sci Transl Med. 2011 May 11;3(82):82ra37. doi: 10.1126/scitranslmed.3002227.

6.

Transforming growth factor-β signaling in motor neuron diseases.

Katsuno M, Adachi H, Banno H, Suzuki K, Tanaka F, Sobue G.

Curr Mol Med. 2011 Feb;11(1):48-56. Review.

PMID:
21189118
7.

TGF-β inhibits muscle differentiation by blocking autocrine signaling pathways initiated by IGF-II.

Gardner S, Alzhanov D, Knollman P, Kuninger D, Rotwein P.

Mol Endocrinol. 2011 Jan;25(1):128-37. doi: 10.1210/me.2010-0292. Epub 2010 Nov 24.

8.

Transforming growth factor-beta1 upregulates myostatin expression in mouse C2C12 myoblasts.

Budasz-Rwiderska M, Jank M, Motyl T.

J Physiol Pharmacol. 2005 Jun;56 Suppl 3:195-214.

9.

Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.

Rhodes SD, Wu X, He Y, Chen S, Yang H, Staser KW, Wang J, Zhang P, Jiang C, Yokota H, Dong R, Peng X, Yang X, Murthy S, Azhar M, Mohammad KS, Xu M, Guise TA, Yang FC.

J Bone Miner Res. 2013 Dec;28(12):2476-89. doi: 10.1002/jbmr.1992.

10.

The Inhibitory Core of the Myostatin Prodomain: Its Interaction with Both Type I and II Membrane Receptors, and Potential to Treat Muscle Atrophy.

Ohsawa Y, Takayama K, Nishimatsu S, Okada T, Fujino M, Fukai Y, Murakami T, Hagiwara H, Itoh F, Tsuchida K, Hayashi Y, Sunada Y.

PLoS One. 2015 Jul 30;10(7):e0133713. doi: 10.1371/journal.pone.0133713. eCollection 2015.

11.

Increased Smad signaling and reduced MRF expression in skeletal muscle from obese subjects.

Watts R, McAinch AJ, Dixon JB, O'Brien PE, Cameron-Smith D.

Obesity (Silver Spring). 2013 Mar;21(3):525-8. doi: 10.1002/oby.20070.

12.

Smad2 and 3 transcription factors control muscle mass in adulthood.

Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, Sandri M.

Am J Physiol Cell Physiol. 2009 Jun;296(6):C1248-57. doi: 10.1152/ajpcell.00104.2009. Epub 2009 Apr 8.

13.

The role of myostatin and bone morphogenetic proteins in muscular disorders.

Tsuchida K.

Expert Opin Biol Ther. 2006 Feb;6(2):147-54. Review.

PMID:
16436040
14.
15.

Mammalian Mss51 is a skeletal muscle-specific gene modulating cellular metabolism.

Moyer AL, Wagner KR.

J Neuromuscul Dis. 2015;2(4):371-385. Epub 2015 Sep 21.

16.
17.

PI3 kinase regulation of skeletal muscle hypertrophy and atrophy.

Glass DJ.

Curr Top Microbiol Immunol. 2010;346:267-78. doi: 10.1007/82_2010_78. Review.

PMID:
20593312
18.

Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.

Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC.

Nat Med. 2007 Feb;13(2):204-10. Epub 2007 Jan 21. Erratum in: Nat Med. 2007 Apr;13(4):511.

19.

Transforming growth factor-beta inhibition of insulin-like growth factor-binding protein-5 synthesis in skeletal muscle cells involves a c-Jun N-terminal kinase-dependent pathway.

Rousse S, Lallemand F, Montarras D, Pinset C, Mazars A, Prunier C, Atfi A, Dubois C.

J Biol Chem. 2001 Dec 14;276(50):46961-7. Epub 2001 Oct 11.

20.

[Myostatin blockade therapy for muscular atrophy].

Sunada Y.

Brain Nerve. 2011 Nov;63(11):1271-7. Japanese.

PMID:
22068480

Supplemental Content

Support Center